Tenofovir 1% gel is an investigational vaginal microbicide intended to reduce the risk of
transmission of HIV. Pregnant women and mothers who have recently given birth often maintain
sexual activity, and research has shown that they may be at greater risk of HIV infection
during pregnancy. Microbicides may be able to prevent HIV infection during pregnancy, which
would also prevent fetal exposure to HIV. This study will test the safety of using tenofovir
1% gel in healthy, pregnant women and healthy, breastfeeding women.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)